IL293266B2 - Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function - Google Patents

Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function

Info

Publication number
IL293266B2
IL293266B2 IL293266A IL29326622A IL293266B2 IL 293266 B2 IL293266 B2 IL 293266B2 IL 293266 A IL293266 A IL 293266A IL 29326622 A IL29326622 A IL 29326622A IL 293266 B2 IL293266 B2 IL 293266B2
Authority
IL
Israel
Prior art keywords
acetyl
leucine
subject
pharmaceutically acceptable
treatment
Prior art date
Application number
IL293266A
Other languages
English (en)
Hebrew (he)
Other versions
IL293266A (en
IL293266B1 (en
Original Assignee
Intrabio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intrabio Ltd filed Critical Intrabio Ltd
Publication of IL293266A publication Critical patent/IL293266A/en
Publication of IL293266B1 publication Critical patent/IL293266B1/en
Publication of IL293266B2 publication Critical patent/IL293266B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
IL293266A 2016-04-19 2017-04-19 Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function IL293266B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201606834 2016-04-19
PCT/GB2017/051090 WO2017182802A1 (en) 2016-04-19 2017-04-19 Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function

Publications (3)

Publication Number Publication Date
IL293266A IL293266A (en) 2022-07-01
IL293266B1 IL293266B1 (en) 2024-03-01
IL293266B2 true IL293266B2 (en) 2024-07-01

Family

ID=58633040

Family Applications (3)

Application Number Title Priority Date Filing Date
IL293266A IL293266B2 (en) 2016-04-19 2017-04-19 Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function
IL310508A IL310508A (en) 2016-04-19 2017-04-19 Acetyl-leucine or its acceptable pharmacy salt for improved mobility and cognitive function
IL262379A IL262379B (en) 2016-04-19 2017-04-19 Acetyl-leucine or its acceptable pharmacy salt for improved mobility and cognitive function

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL310508A IL310508A (en) 2016-04-19 2017-04-19 Acetyl-leucine or its acceptable pharmacy salt for improved mobility and cognitive function
IL262379A IL262379B (en) 2016-04-19 2017-04-19 Acetyl-leucine or its acceptable pharmacy salt for improved mobility and cognitive function

Country Status (27)

Country Link
US (4) US10905670B2 (OSRAM)
EP (2) EP3445351B1 (OSRAM)
JP (3) JP7387264B2 (OSRAM)
KR (4) KR102791288B1 (OSRAM)
CN (2) CN118593463A (OSRAM)
AU (2) AU2017252507B2 (OSRAM)
BR (1) BR112018071547A2 (OSRAM)
CA (1) CA3021155A1 (OSRAM)
DK (1) DK3445351T3 (OSRAM)
ES (1) ES2994242T3 (OSRAM)
FI (1) FI3445351T3 (OSRAM)
HR (1) HRP20241552T1 (OSRAM)
HU (1) HUE069219T2 (OSRAM)
IL (3) IL293266B2 (OSRAM)
LT (1) LT3445351T (OSRAM)
MD (1) MD3445351T2 (OSRAM)
MX (2) MX388461B (OSRAM)
NZ (1) NZ747307A (OSRAM)
PL (1) PL3445351T3 (OSRAM)
PT (1) PT3445351T (OSRAM)
RS (1) RS66142B1 (OSRAM)
RU (1) RU2745912C2 (OSRAM)
SG (2) SG11201809031XA (OSRAM)
SI (1) SI3445351T1 (OSRAM)
SM (1) SMT202400459T1 (OSRAM)
WO (1) WO2017182802A1 (OSRAM)
ZA (1) ZA201806849B (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102791288B1 (ko) * 2016-04-19 2025-04-03 인트라바이오 리미티드 이동성 및 인지 기능을 개선시키기 위한 아세틸-류신 또는 이의 약제학적으로 허용되는 염
AU2017308865B2 (en) 2016-08-11 2023-04-13 Intrabio Limited Therapeutic agents for neurodegenerative diseases
GB201709459D0 (en) 2017-06-14 2017-07-26 Intrabio Ltd Treatment for migraine
JP7471298B2 (ja) 2018-12-06 2024-04-19 イントラビオ エルティーディー アセチル－ロイシンの重水素化類似体
SI3934637T1 (sl) * 2019-03-02 2024-10-30 Intrabio Ltd Summit House (N-)acetil-L-levcin za uporabo pri zdravljenju travmatske poškodbe možganov
US12171852B1 (en) 2023-07-18 2024-12-24 Sytheon Ltd Composition and methods for regulating melanogenesis
US12403111B2 (en) 2024-02-02 2025-09-02 SynGAP Research Fund Compositions and methods for treating neurodevelopmental disorders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008032222A2 (en) * 2006-09-13 2008-03-20 Pierre Fabre Medicament Treatment of vertigo with acetyl-l-leucine

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060063827A1 (en) * 2004-09-23 2006-03-23 Yu Ruey J Systemic administration of therapeutic amino acids and N-acetylamino acids
US20070190070A1 (en) * 2004-09-03 2007-08-16 Zeldis Jerome B Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
FR2883180B1 (fr) * 2005-03-18 2007-05-25 Pierre Fabre Medicament Sa Utilisation de l'acetyl-leucine pour la preparation d'un medicament destine au traitement de troubles de l'equilibre
US20080097606A1 (en) * 2006-10-19 2008-04-24 Cragg Andrew H Knee joint prosthesis and hyaluronate compositions for treatment of osteoarthritis
EP2152280A1 (en) * 2007-05-08 2010-02-17 Northern Innovations And Formulations Corp. Branched-chain amino acid composition for improving skeletal muscle protein metabolism
US20120196257A1 (en) * 2009-08-27 2012-08-02 Joe Verghese Cognitive function training to improve motor ability
TN2010000251A1 (fr) * 2010-06-03 2011-11-11 Rekik Raouf N-acetyl-dl-leucine medicament neuro et retino protecteur
WO2012060844A1 (en) * 2010-11-05 2012-05-10 Biotie Therapies, Inc A2a antagonists as cognition and motor function enhancers
TN2010000566A1 (en) * 2010-12-03 2012-05-24 Rekik Raouf Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs
KR102791288B1 (ko) 2016-04-19 2025-04-03 인트라바이오 리미티드 이동성 및 인지 기능을 개선시키기 위한 아세틸-류신 또는 이의 약제학적으로 허용되는 염
WO2019079536A1 (en) * 2017-10-18 2019-04-25 Intrabio Ltd THERAPEUTIC AGENTS FOR IMPROVED MOBILITY AND COGNITIVE FUNCTION AND FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES AND LYSOSOMAL STORAGE DISORDERS

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008032222A2 (en) * 2006-09-13 2008-03-20 Pierre Fabre Medicament Treatment of vertigo with acetyl-l-leucine

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MICHAEL STRUPP ET AL,, EFFECTS OF ACETYL-DL-LEUCINE IN PATIENTS WITH CEREBELLAR ATAXIA: A CASE SERIES, 9 July 2013 (2013-07-09) *
TATIANA BREMOVA ET AL,, ACETYL-DL-LEUCINE IN NIEMANN-PICK TYPE C: A CASE SERIES, 20 October 2015 (2015-10-20) *
TIGHILET BRAHIM ET AL,, COMPARATIVE ANALYSIS OF PHARMACOLOGICAL TREATMENTS WITH N-ACETYL-DL-LEUCINE (TANGANIL) AND ITS TWO ISOMERS (N-ACETYL-L-LEUCINE AND N-ACETYL-D-LEUCINE) ON VESTIBULAR COMPENSATION: BEHAVIORAL INVESTIGATION IN THE CAT, 19 November 2015 (2015-11-19) *

Also Published As

Publication number Publication date
JP2019513814A (ja) 2019-05-30
LT3445351T (lt) 2024-11-25
AU2022256077A1 (en) 2022-11-17
EP3445351A1 (en) 2019-02-27
KR20240018683A (ko) 2024-02-13
FI3445351T3 (fi) 2024-11-18
MX2018012739A (es) 2019-06-17
KR20180134398A (ko) 2018-12-18
MD3445351T2 (ro) 2024-12-31
AU2017252507B2 (en) 2022-07-21
ES2994242T3 (en) 2025-02-05
HRP20241552T1 (hr) 2025-01-17
JP2022024058A (ja) 2022-02-08
EP3445351B1 (en) 2024-10-16
CN109069463B (zh) 2024-07-23
IL293266A (en) 2022-07-01
NZ747307A (en) 2025-10-31
US12329733B2 (en) 2025-06-17
EP4501406A3 (en) 2025-03-26
IL293266B1 (en) 2024-03-01
ZA201806849B (en) 2019-07-31
IL262379B (en) 2022-07-01
BR112018071547A2 (pt) 2019-03-06
JP2024123087A (ja) 2024-09-10
CA3021155A1 (en) 2017-10-26
WO2017182802A1 (en) 2017-10-26
KR20220093386A (ko) 2022-07-05
RU2745912C2 (ru) 2021-04-02
KR20220038814A (ko) 2022-03-29
US20250332133A1 (en) 2025-10-30
CN118593463A (zh) 2024-09-06
AU2017252507A1 (en) 2018-11-08
SG10202106190RA (en) 2021-07-29
JP7387264B2 (ja) 2023-11-28
MX388461B (es) 2025-03-20
PT3445351T (pt) 2024-11-14
SMT202400459T1 (it) 2025-01-14
KR102791288B1 (ko) 2025-04-03
IL262379A (en) 2018-11-29
IL310508A (en) 2024-03-01
RU2018140131A (ru) 2020-05-14
KR102632670B1 (ko) 2024-02-01
SI3445351T1 (sl) 2025-04-30
HUE069219T2 (hu) 2025-02-28
EP4501406A2 (en) 2025-02-05
US20190083438A1 (en) 2019-03-21
US10905670B2 (en) 2021-02-02
DK3445351T3 (da) 2024-11-04
US20230346732A1 (en) 2023-11-02
KR102413754B1 (ko) 2022-06-27
US11998518B2 (en) 2024-06-04
MX2021014844A (es) 2022-01-18
JP7506046B2 (ja) 2024-06-25
RS66142B1 (sr) 2024-12-31
PL3445351T3 (pl) 2025-01-07
US20210106548A1 (en) 2021-04-15
CN109069463A (zh) 2018-12-21
SG11201809031XA (en) 2018-11-29
RU2021107001A (ru) 2021-04-12
RU2018140131A3 (OSRAM) 2020-05-14

Similar Documents

Publication Publication Date Title
US12329733B2 (en) Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function
AU2023202121B2 (en) Therapeutic agents for neurodegenerative diseases
US12458614B2 (en) Therapeutic agents for improved mobility and cognitive function and for treating neurodegenerative diseases and lysosomal storage disorders
RU2837641C2 (ru) Ацетиллейцин или его фармацевтически приемлемая соль для улучшения двигательной функции и когнитивной функции
HK40114671A (en) Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function
HK1262576B (en) Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility
HK1262576A1 (en) Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility
NZ787419A (en) Acetyl-Leucine or a Pharmaceutically Acceptable Salt Thereof for Improved Mobility and Cognitive
BR122024012307A2 (pt) Uso de acetil-leucina ou um sal farmaceuticamente aceitável desta